Design, synthesis, and anti-necroptotic activity of novel Phenylbenzothiazole receptor-interacting protein kinase 1 (RIPK1) inhibitors
Bioorganic & Medicinal Chemistry Letters · 2026
DOI: 10.1016/j.bmcl.2026.130613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026. Verfasst von Jing Tao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Natural and Biomimetic Drugs Research, College of Pharmacy, Jiangxi Normal University, 99 Ziyang Road, Nanchang …. Hauptthemen laut MEDLINE: Drug Design, Receptor-Interacting Protein Serine-Threonine Kinases, Benzothiazoles, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Jiangxi Provincial Natural Science Foundation.
Abstract (Originalsprache)
Receptor-interacting protein kinase 1 (RIPK1) is a central regulator of necroptosis and a promising therapeutic target for inflammatory and degenerative diseases. Guided by computer-aided drug design (CADD) and structure-based optimizations, we developed a series of phenylbenzothiazole derivatives to enhance RIPK1 inhibition. A total of 36 analogs were efficiently synthesized and fully characterized, incorporating systematic modifications at the R(Degterev et al., 20051), R(Vanlangenakker et al., 20122), and R3 positions. Their anti-necroptotic activity was evaluated in HT-29 cells under TNF-induced necroptosis. Several compounds (27, 43, 44, and 51) demonstrated significantly improved potency over the lead molecule 18. SAR analysis revealed that CF3 or OCF3 at R(Degterev et al., 20051), F or H at R(Vanlangenakker et al., 20122), and 3-oxocyclobutyl or 3-oxocyclopentyl groups at R3 greatly enhanced activity, indicating more favorable interactions within the RIPK1 binding pocket. These findings identify new phenylbenzothiazole-based inhibitors with promising anti-necroptotic effects and highlight key structural features for future optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi Provincial Key Laboratory of Natural and Biomimetic Drugs Research, College of Pharmacy, Jiangxi Normal University, 99 Ziyang Road, Nanchang 330022, China.
- Institute of Flow Chemistry and Engineering, School of Chemistry and Materials, Jiangxi Normal University, 99 Ziyang Road, Nanchang 330022, China.
- Jiangxi Provincial Key Laboratory of Natural and Biomimetic Drugs Research, College of Pharmacy, Jiangxi Normal University, 99 Ziyang Road, Nanchang 330022, China. Electronic address: tyuan@jxnu.edu.cn.
- Jiangxi Provincial Key Laboratory of Natural and Biomimetic Drugs Research, College of Pharmacy, Jiangxi Normal University, 99 Ziyang Road, Nanchang 330022, China; Institute of Flow Chemistry and Engineering, School of…
Förderung
- Jiangxi Provincial Natural Science Foundation
Zitieren
APA
Tao, J., Xu, Y., Chen, Z., Liu, Y., Zuo, X., Yuan, T., & Yao, H. (2026). Design, synthesis, and anti-necroptotic activity of novel Phenylbenzothiazole receptor-interacting protein kinase 1 (RIPK1) inhibitors. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2026.130613
Vancouver
Tao J, Xu Y, Chen Z, Liu Y, Zuo X, Yuan T, et al. Design, synthesis, and anti-necroptotic activity of novel Phenylbenzothiazole receptor-interacting protein kinase 1 (RIPK1) inhibitors. Bioorganic & Medicinal Chemistry Letters. 2026. doi:10.1016/j.bmcl.2026.130613
BibTeX
@article{Tao2026,
author = {Tao, Jing and Xu, Yuelun and Chen, Zijun and Liu, Yang and Zuo, Xiong and Yuan, Tao and Yao, Houzong},
title = {Design, synthesis, and anti-necroptotic activity of novel Phenylbenzothiazole receptor-interacting protein kinase 1 (RIPK1) inhibitors},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2026},
doi = {10.1016/j.bmcl.2026.130613}
}
EUVIMED